S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:CDXS

Codexis - CDXS Stock Forecast, Price & News

$5.67
+0.04 (+0.71%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.31
$5.69
50-Day Range
$4.98
$6.84
52-Week Range
$4.81
$35.35
Volume
521,506 shs
Average Volume
1.03 million shs
Market Capitalization
$372.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

Codexis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
246.9% Upside
$19.67 Price Target
Short Interest
Bearish
7.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$411,448 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.50) to ($0.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

756th out of 1,034 stocks

Industrial Organic Chemicals Industry

15th out of 20 stocks

CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

Codexis (NASDAQ:CDXS) Raised to Hold at StockNews.com
Codexis Third Quarter 2022 Earnings: Beats Expectations
When Should You Buy Codexis, Inc. (NASDAQ:CDXS)?
Codexis: Q2 Earnings Snapshot
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
11/03/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.67
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+246.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-21,280,000.00
Pretax Margin
-23.35%

Debt

Sales & Book Value

Annual Sales
$104.75 million
Book Value
$2.35 per share

Miscellaneous

Free Float
61,089,000
Market Cap
$372.46 million
Optionable
Optionable
Beta
1.45

Key Executives

  • Dr. Stephen George Dilly MBBS (Age 62)
    Ph.D., Pres, CEO & Director
    Comp: $75k
  • Mr. Ross Taylor Jr. (Age 59)
    M.B.A., Sr. VP & CFO
    Comp: $667.31k
  • Mr. John J. NicolsMr. John J. Nicols (Age 58)
    Director & Strategic Advisor
    Comp: $1.33M
  • Mr. Kevin Norrett M.B.A. (Age 49)
    M.S., Chief Operating Officer
  • Ms. Margaret Fitzgerald J.D.
    Chief Legal and Compliance Officer, Gen. Counsel & Sec.
  • Ms. Asli Aras Ph.D.
    VP & Head of Corp. Devel.
  • Ms. Karen Frechou-Armijo
    Sr. VP & Head of HR
  • Mr. Rob Wilson Ph.D.
    Sr. VP & GM of Performance Enzymes
  • Dr. Karl A. Schoene Ph.D.
    Sr. VP of Devel. & Operations
  • Dr. Stefan Lutz Ph.D.
    Sr. VP of Research













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2023?

4 analysts have issued 1 year price targets for Codexis' stock. Their CDXS share price forecasts range from $15.00 to $22.00. On average, they anticipate the company's stock price to reach $19.67 in the next twelve months. This suggests a possible upside of 246.9% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2022?

Codexis' stock was trading at $31.27 on January 1st, 2022. Since then, CDXS shares have decreased by 81.9% and is now trading at $5.67.
View the best growth stocks for 2022 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03. The biotechnology company had revenue of $34.47 million for the quarter, compared to the consensus estimate of $31.41 million. Codexis had a negative net margin of 23.49% and a negative trailing twelve-month return on equity of 19.59%.

What guidance has Codexis issued on next quarter's earnings?

Codexis updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.10 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.79%), BlackRock Inc. (8.34%), ARK Investment Management LLC (6.53%), Vanguard Group Inc. (5.35%), Telemark Asset Management LLC (4.12%) and Nuveen Asset Management LLC (2.14%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $5.67.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $372.46 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Codexis have?

The company employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 12/4/2022 by MarketBeat.com Staff